Overview
Dr. James Xu received a bachelor of science in chemical engineering with a minor in mathematics from Brigham Young University and his medical degree from University of Minnesota. He completed his internal medicine residency at the Yale-New Haven Hospital of Yale University in New Haven, CT, and his hematology and medical oncology fellowship at the New York-Presbyterian Hospital of Columbia University in New York City. Because of his unique background in engineering and medicine, Dr. Xu was the recipient of the American Society of Clinical Oncology-Conquer Cancer Foundation Young Investigator Award in 2011 and Merit Award in 2012. Dr. Xu is a strong advocate of precision medicine and he is the first person to have proposed and preliminarily confirmed the feasibility of using deep sequencing technology to detect genetic mutation in rare cell samples such as circulating tumor cells from cancer patients’ peripheral blood. He has published in peer-reviewed journals in lung, breast, and pancreatic cancers.
Dr. Xu is highly rated in 10 conditions, according to our data. His top areas of expertise are Pulmonary Embolism, Deep Vein Thrombosis, Protein S Deficiency, and Hereditary Resistance to Anti-Vitamin K.
His clinical research consists of co-authoring 5 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Residency
Specialties
Licenses
Board Certifications
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
Suite 501, Rockville, MD 20852
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
The Center For Cancer & Blood Disorders
Dr. Ralph V. Boccia is a hematologist affiliated with Sibley Memorial Hospital, Suburban Hospital, Shady Grove Adventist Hospital, Holy Cross Hospital and MedStar Georgetown University Hospital, where he is a clinical associate professor of medicine for the University, as well as the medical director of the International Oncology Network (ION) Clinical Research Program and the chairman of ION’s Medical Advisory Panel. He practices out of the Center for Cancer and Blood Disorders, of which he is the founder and medical director, located in Bethesda, Maryland and Germantown, Maryland. Dr. Boccia earned his medical degree from the Autonomous University of Guadalajara School of Medicine. He completed a residency in internal medicine at Kern Medical Center, followed by a fellowship in hematology, oncology and bone marrow transplant at the combined UCLA-Veterans Administration Program and The National Cancer Institute at the National Institutes of Health. Dr. Boccia is a member of the American College of Physicians, the American Society of Clinical Oncology, the American Society of Hematology and the American Society for Blood and Marrow Transplantation. Dr. Boccia has been listed as a Top Doctor by Washingtonian Magazine and Consumers’ Checkbook Magazine since 1992. He has also been recognized as a Super Doctor by The Washington Post Magazine and a Regional Top Doctor for Washington, D.C., Baltimore and Washington-Baltimore by Castle Connolly. Dr. Boccia has contributed to various articles with his research, published in journals such as Annals of Internal Medicine, Journal of Clinical Oncology and The Lancet. Recent News Articles and Media Coverage Bladder cancer trends in Montgomery and Prince George's counties: Welcome news - and 3 facts you need to know. NJ.com (08/16/2016) RCCA Expands to Maryland to Become One of the Nation's First Multi-State Oncology/Hematology Physician-Owned and -Operated Networks. OncLive (10/06/2015). Dr. Boccia is highly rated in 25 conditions, according to our data. His top areas of expertise are Anemia, Multiple Myeloma, Thrombocytopenia, Adult Immune Thrombocytopenia, and Splenectomy.
Sidney Kimmel Comprehensive Cancer Center
Dr. Ivana Gojo is a Hematologist/Oncologist in Baltimore. Her clinical focus is on diagnosis and management of patients with acute leukemias (AML, ALL) and other myeloid malignancies (MDS, MPNs, CML), with emphasis on the development of novel therapeutic approaches for these diseases. She is nationally and internationally recognized expert in clinical translation of novel therapeutics for acute leukemias and principal investigator on multiple multi-center investigator-initiated studies. Dr. Gojo joined the Johns Hopkins faculty in 2012 as the Co-Director of Leukemia Drug Development Program. She has served on the National Cancer Institute (NCI) Investigational Drug Steering Committee since 2014. Dr. Gojo received a Service Star Award from Johns Hopkins Medicine Service Excellence in 2018 for her exemplary care of leukemia patients. Dr. Gojo contributed to the clinical translational and drug development effort of multiple novel agents targeting pathogenic pathways in patients with acute leukemia. Her research efforts are now concentrated on the development and integration of novel immunotherapies into therapeutic armamentarium for patients with acute leukemia. She mentors basic and clinical research fellows and junior faculty on the development and design of novel clinical trials and mechanistic laboratory studies associated with these trials. She served as a leukemia team leader on the National Institute of Health (NIH)/NCI N01 grant (Phase II consortium) (2009-2011), and is co-principal investigator (PI) on the Experimental Therapeutics (ET)-Clinical Trial Network (CTN) UM1 grant supporting early clinical trials. Dr. Gojo has served on the National Comprehensive Cancer Network guideline panel for AML since 2019, Myeloid Growth Factor guideline panel since 2015 and previously served on the MPNs guideline panel (2016-2019). She has extensive experience in the regulatory aspects of drug development and served as the Chair (2015-2016) and Co-Chair (2014-2015) of the Cancer Research Review Committee at Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, and serves as a member of the SKCCC Biostatistics Core Advisory Committee and SKCCC Clinical Research Office Coordinating Center Oversight Committee. Dr. Gojo is highly rated in 16 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.
Maryland Oncology Hematology
As an active participant in the medical community, Mohit Narang, M.D. has served as a primary investigator and research assistant on many trials. During Dr. Narang’s fellowship, he was honored with the invitation to attend the Masterclass in Clinical Oncology at Montecatini, Italy by the European School of Oncology. He holds professional memberships with the American Society of Clinical Oncology, American Society of Hematology, as well as the European Society of Medical Oncology. Learn more at marylandoncology.com. Dr. Narang is highly rated in 43 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Agranulocytosis, Paget Disease of the Breast, Thrombocytopenia, and Bone Marrow Transplant.
Frequently Asked Questions about Dr. James X. Xu
How do I make an appointment with Dr. James X. Xu?
You can book an appointment with Dr. James X. Xu by calling their office at 240-618-0275. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. James X. Xu a top-rated expert for Pulmonary Embolism?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. James X. Xu is classified as an Distinguished expert for Pulmonary Embolism, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. James X. Xu specialize in?
While Dr. James X. Xu is a Hematology Oncology, they have specific expertise in Pulmonary Embolism, Deep Vein Thrombosis, and Protein S Deficiency. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.
Does Dr. James X. Xu participate in research or clinical trials?
Yes. Dr. James X. Xu has published 5 articles and abstracts on conditions like Pulmonary Embolism. You can view a list of Dr. James X. Xu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. James X. Xu accept my insurance?
Dr. James X. Xu accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 240-618-0275 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Pulmonary EmbolismDr. Xu isDistinguished. Learn about Pulmonary Embolism.
- Advanced
- AnemiaDr. Xu isAdvanced. Learn about Anemia.
- Childhood Iron Deficiency Anemia
- Congenital Antithrombin 3 Deficiency
- Deep Vein ThrombosisDr. Xu isAdvanced. Learn about Deep Vein Thrombosis.
- Hereditary Resistance to Anti-Vitamin K
- Iron Deficiency AnemiaDr. Xu isAdvanced. Learn about Iron Deficiency Anemia.
- Experienced
- Acute Hepatic Porphyria (AHP)Dr. Xu isExperienced. Learn about Acute Hepatic Porphyria (AHP).
- Acute Mountain SicknessDr. Xu isExperienced. Learn about Acute Mountain Sickness.
- Adult Immune ThrombocytopeniaDr. Xu isExperienced. Learn about Adult Immune Thrombocytopenia.
- AgranulocytosisDr. Xu isExperienced. Learn about Agranulocytosis.
- ALK-Positive Non-Small Cell Lung Cancer
- Alpha ThalassemiaDr. Xu isExperienced. Learn about Alpha Thalassemia.

